Pharmacom Biovet Financials
| PHMB Stock | USD 0.0001 0.00 0.00% |
The essential information of the day-to-day investment outlook for Pharmacom Biovet includes many different criteria found on its balance sheet. An individual investor should monitor Pharmacom Biovet's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pharmacom Biovet.
Net Income |
|
Pharmacom | Select Account or Indicator |
Understanding current and past Pharmacom Biovet Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pharmacom Biovet's financial statements are interrelated, with each one affecting the others. For example, an increase in Pharmacom Biovet's assets may result in an increase in income on the income statement.
Please note, the presentation of Pharmacom Biovet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pharmacom Biovet's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pharmacom Biovet's management manipulating its earnings.
Pharmacom Biovet Stock Summary
Pharmacom Biovet competes with IMAC Holdings, P3 Health, and HCA Holdings. PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. PharmaCom BioVet, Inc. was incorporated in 1995 and is headquartered in Raleigh, North Carolina. PHARMACOM BIOVET operates under Medical Care Facilities classification in the United States and is traded on PNK Exchange.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | OTCCE Exchange |
| ISIN | US71720A1079 |
| Business Address | 6040-A Six Forks |
| Sector | Health Care Providers & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Phone | 919 604 4887 |
| Currency | USD - US Dollar |
Pharmacom Biovet Key Financial Ratios
| Net Income | (556.18 K) | ||||
| Total Asset | 112.36 K | ||||
| Retained Earnings | (19.05 M) |
Pharmacom Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharmacom Biovet's current stock value. Our valuation model uses many indicators to compare Pharmacom Biovet value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmacom Biovet competition to find correlations between indicators driving Pharmacom Biovet's intrinsic value. More Info.Pharmacom Biovet is rated below average in current valuation category among its peers. It is regarded second in net income category among its peers . At present, Pharmacom Biovet's Net Loss is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmacom Biovet's earnings, one of the primary drivers of an investment's value.Pharmacom Biovet Systematic Risk
Pharmacom Biovet's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pharmacom Biovet volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Pharmacom Biovet correlated with the market. If Beta is less than 0 Pharmacom Biovet generally moves in the opposite direction as compared to the market. If Pharmacom Biovet Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pharmacom Biovet is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pharmacom Biovet is generally in the same direction as the market. If Beta > 1 Pharmacom Biovet moves generally in the same direction as, but more than the movement of the benchmark.
About Pharmacom Biovet Financials
What exactly are Pharmacom Biovet Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Pharmacom Biovet's income statement, its balance sheet, and the statement of cash flows. Potential Pharmacom Biovet investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Pharmacom Biovet investors may use each financial statement separately, they are all related. The changes in Pharmacom Biovet's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pharmacom Biovet's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Complementary Tools for Pharmacom Stock analysis
When running Pharmacom Biovet's price analysis, check to measure Pharmacom Biovet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmacom Biovet is operating at the current time. Most of Pharmacom Biovet's value examination focuses on studying past and present price action to predict the probability of Pharmacom Biovet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmacom Biovet's price. Additionally, you may evaluate how the addition of Pharmacom Biovet to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |